GABTX | VTCAX | GABTX / VTCAX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 31 years | 20 years | - |
Gain YTD | 22.859 | 33.002 | 69% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 100000 | 1% |
Min. Initial Investment IRA | 250 | N/A | - |
Net Assets | 66.4M | 4.64B | 1% |
Annual Yield % from dividends | 0.30 | 0.94 | 32% |
Returns for 1 year | 23.59 | 33.07 | 71% |
Returns for 3 years | 5.40 | 16.44 | 33% |
Returns for 5 years | 20.78 | 66.00 | 31% |
Returns for 10 years | 4.52 | 84.41 | 5% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
RYOAX | 52.14 | 0.60 | +1.16% |
Rydex Biotechnology H | |||
IVOAX | 18.21 | 0.20 | +1.11% |
Delaware Ivy Mid Cap Income Opps A | |||
GSDPX | 47.44 | 0.48 | +1.02% |
Goldman Sachs US Tax-Managed Eq P | |||
GRHIX | 12.25 | 0.03 | +0.25% |
Goehring & Rozencwajg Resources Instl | |||
VEMIX | 28.06 | -0.16 | -0.56% |
Vanguard Emerging Mkts Stock Idx Instl |